Related Experiment Videos
Adjuvant chemotherapy for primary breast cancer
Monica Fornier1, Clifford Hudis
1Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 457, New York, NY 10021, USA. fornierm@mskcc.org
Current Oncology Reports
|December 22, 2004
Summary
Adjuvant chemotherapy improves outcomes for early-stage breast cancer patients. Recent advances in chemotherapy agents and schedules offer better results, especially for those with lymph node involvement.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Research
Background:
- Adjuvant chemotherapy is crucial for hormone-unresponsive/high-risk early-stage breast cancer.
- Prognosis remains poor for patients with extensive axillary lymph node involvement.
- Recent advancements aim to improve clinical outcomes in breast cancer treatment.
Purpose of the Study:
- To summarize the current state of adjuvant chemotherapy for primary breast carcinoma.
- To highlight recent developments and novel approaches in adjuvant chemotherapy.
Main Methods:
- Literature review of recent studies and clinical trials.
- Analysis of new chemotherapy agents and administration schedules.
- Synthesis of current evidence on adjuvant chemotherapy efficacy.
Main Results:
- Adjuvant chemotherapy significantly reduces relapse and mortality risks.
- Novel agents and schedules demonstrate improved clinical outcomes.
- Effective management strategies are evolving for high-risk early-stage breast cancer.
Conclusions:
- Adjuvant chemotherapy remains a cornerstone in treating operable early-stage breast cancer.
- Ongoing research into new agents and schedules is vital for improving patient survival.
- Personalized treatment approaches are essential for patients with poor prognostic factors.